You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 7, 2025

Drug Price Trends for NDC 55513-0504


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 55513-0504

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
LUMAKRAS 320MG TAB Amgen USA, Inc. 55513-0504-50 90 19708.32 218.98133 2024-01-01 - 2026-01-31 FSS
LUMAKRAS 320MG TAB Amgen USA, Inc. 55513-0504-50 90 15346.84 170.52044 2023-05-27 - 2026-01-31 Big4
LUMAKRAS 320MG TAB Amgen USA, Inc. 55513-0504-50 90 19807.36 220.08178 2023-05-27 - 2026-01-31 FSS
LUMAKRAS 320MG TAB Amgen USA, Inc. 55513-0504-50 90 15125.44 168.06044 2023-09-22 - 2026-01-31 Big4
LUMAKRAS 320MG TAB Amgen USA, Inc. 55513-0504-50 90 19807.36 220.08178 2023-09-22 - 2026-01-31 FSS
LUMAKRAS 320MG TAB Amgen USA, Inc. 55513-0504-50 90 14994.32 166.60356 2024-01-01 - 2026-01-31 Big4
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for LUMAKRAS (Sotorasib)

Introduction to LUMAKRAS

LUMAKRAS, with the active ingredient sotorasib, is a targeted therapy approved for the treatment of adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC)[1].

Market Context

The NSCLC market is one of the most significant segments in the oncology therapeutic area, driven by the increasing incidence of lung cancer and the development of innovative treatments.

Growth Drivers

  • Immunotherapies and Targeted Therapies: The NSCLC market is expected to grow significantly due to the adoption of premium-priced immune checkpoint inhibitors and targeted therapies. By 2025, immunotherapies are projected to account for roughly 65% of total sales in the NSCLC market, with key players like Keytruda, Opdivo, and Tecentriq leading the market[4].

Competitive Landscape

  • Key Competitors: LUMAKRAS competes in a market dominated by other targeted therapies such as Tagrisso (osimertinib) and Avastin (bevacizumab). Tagrisso, for instance, is projected to achieve blockbuster status by 2025 with estimated sales of $1.7 billion[4].

Clinical and Commercial Performance

Clinical Trials and Approval

  • LUMAKRAS was evaluated in the CodeBreaK 100 clinical trial, which demonstrated its efficacy in patients with KRAS G12C-mutated NSCLC. The drug received initial U.S. approval in 2021[1].

Patient Population and Market Potential

  • The median age of patients treated with LUMAKRAS is 66 years, with a significant portion being female and predominantly White. This demographic data indicates a substantial market potential given the prevalence of NSCLC in this age group[1].

Price Projections and Market Dynamics

Pricing Factors

  • The pricing of LUMAKRAS, like other biopharmaceuticals, is influenced by several factors including the number of competitors, the drug's efficacy, and the costs associated with research and development. Manufacturers often attribute price increases to rebates, co-pay assistance programs, and shareholder obligations[2].

Market Forecast

  • While specific price projections for LUMAKRAS are not readily available, the overall NSCLC market is expected to see significant growth. Targeted therapies, including LUMAKRAS, are anticipated to contribute substantially to this growth, with sales projected to reach $9.4 billion by 2025[4].

Regulatory and Economic Considerations

Regulatory Landscape

  • The regulatory environment for biopharmaceuticals is evolving to keep pace with innovation. This includes more flexible clinical trial designs and a focus on patient-centered care, which can impact the pricing and market access of drugs like LUMAKRAS[3].

Economic Impact

  • The cost of LUMAKRAS, like other biologics, is a significant factor in healthcare expenditure. Health insurers and patients often face high costs, which can be mitigated by generics or biosimilars once patents expire. However, for LUMAKRAS, given its recent approval, such alternatives are not yet available[2].

Unmet Needs and Future Outlook

Unmet Needs in NSCLC

  • Despite the advancements in NSCLC treatments, there remains an unmet need for more effective and less toxic therapies. LUMAKRAS addresses a specific mutation (KRAS G12C), but the broader NSCLC market still seeks more comprehensive solutions[4].

Future Innovations

  • The biopharma and biotech industries are expected to continue innovating, with a focus on precision medicine, AI/ML technologies, and more efficient clinical trial designs. These innovations could further shape the market for LUMAKRAS and other NSCLC treatments[3].

Key Takeaways

  • Market Growth: The NSCLC market is expected to grow significantly, driven by immunotherapies and targeted therapies.
  • Competitive Landscape: LUMAKRAS competes in a market with established players like Tagrisso and Avastin.
  • Pricing Factors: Pricing is influenced by competition, efficacy, and R&D costs.
  • Regulatory Environment: Evolving regulatory frameworks support innovative clinical trial designs and patient-centered care.
  • Future Outlook: Continued innovation in precision medicine and AI/ML technologies will shape the future of NSCLC treatments.

FAQs

Q1: What is LUMAKRAS used for?

  • LUMAKRAS (sotorasib) is used for the treatment of adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC)[1].

Q2: How does LUMAKRAS compare to other NSCLC treatments?

  • LUMAKRAS is a targeted therapy that competes with other targeted therapies like Tagrisso and Avastin, as well as immunotherapies like Keytruda and Opdivo[4].

Q3: What are the common side effects of LUMAKRAS?

  • Common serious adverse reactions include hepatotoxicity, pneumonia, and diarrhea. Fatal adverse reactions have also been reported, including respiratory failure and pneumonitis[1].

Q4: How is the pricing of LUMAKRAS determined?

  • The pricing of LUMAKRAS is influenced by factors such as the number of competitors, the drug's efficacy, research and development costs, and obligations to shareholders[2].

Q5: What is the projected market size for NSCLC treatments by 2025?

  • The NSCLC market is projected to see significant growth, with immunotherapies reaching $17.5 billion in sales and targeted therapies reaching $9.4 billion by 2025[4].

Sources

  1. DailyMed: LUMAKRAS- sotorasib tablet, coated - DailyMed.
  2. Oregon Department of Consumer and Business Services: Prescription Drug Price Transparency Results and Recommendations.
  3. TFS CRO: 5 Predictions for the Biopharma and Biotech Industries in 2025.
  4. Drug Development & Delivery: NSCLC MARKET - Global Drug Forecast & Market Analysis to 2025.
  5. FDA: National Drug Code Directory - FDA.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.